Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD2 | Q9BYW2 | 13/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.53 |
| ▸ | NSD2 | O96028 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21724842 | 0.82 | SETD2 (0.56) | SETD2HRH4NSD2DRD2CYP2C8 | |
| SCHEMBL7879547 | 0.79 | KDM4E (0.48) | ALDH1A1HPGDKDM4EDRD2TSHR | |
| SCHEMBL7877589 | 0.79 | DRD3 (0.59) | HRH4DRD2 | |
| SCHEMBL25040785 | 0.78 | SETD2 (0.68) | SETD2HRH4NSD2HTR1B | |
| SCHEMBL6662366 | 0.77 | NPC1 (0.52) | ALDH1A1HPGDKDM4EDRD2KMT2A | |
| SCHEMBL25040299 | 0.77 | SETD2 (0.75) | SETD2HRH4NSD2ALDH1A1KDM4E | |
| SCHEMBL25037901 | 0.75 | HRH4 (0.55) | SETD2HRH4NSD2DRD2HTR1B | |
| SCHEMBL25040030 | 0.75 | SETD2 (0.58) | SETD2HRH4NSD2ALDH1A1KDM4E | |
| SCHEMBL5160955 | 0.75 | HTR1A (0.60) | ALDH1A1HPGDKDM4EDRD2 | |
| SCHEMBL5160839 | 0.74 | DRD2 (0.53) | DRD2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | Epizyme, Inc. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | NSD1, NSD3, EHMT1 | SETD2 8/4885HRH4 3748/4885NSD2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.